Streetbeat News

Regulatory

RBLX

The Bear Cave has issued a report titled 'Problems at Roblox (RBLX) #5', which could potentially impact investor sentiment towards Roblox.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 2:32 pm

NCNCW

Trading for NCNCW was halted at 10:29:26 a.m. ET due to pending news. This indicates that significant information regarding the company is expected to be released, which could impact its stock price.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 2:29 pm

NCNC

Trading for a company was halted at 10:29:26 a.m. ET due to pending news. This indicates that significant information is expected to be released, which could impact the company's stock price.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 2:29 pm

INTC

China has launched a security review of Intel's products, citing national security risks amid ongoing trade tensions with the U.S. The review focuses on alleged flaws in Intel's CPU chips and security management. This move comes as Intel faces challenges due to U.S. export restrictions and its significant revenue from China.

Portfolio Pulse from Benzinga Neuro

October 17, 2024 | 2:29 pm

AVDL

Avadel Pharmaceuticals has received FDA approval for LUMRYZ, an extended-release oral suspension for treating cataplexy or excessive daytime sleepiness in narcolepsy patients aged 7 and older. LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for this condition and has been granted Orphan Drug Exclusivity until 2031.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 1:42 pm

BTCUSD

Galaxy Research reports a slowdown in crypto venture capital activity in Q3, with a 20% decrease in investment and a 17% drop in deals. Early-stage investments dominate, while AI-related crypto projects see a surge. The US remains a key hub for crypto VC investment.

Portfolio Pulse from Ivan Crnogatić

October 17, 2024 | 1:16 pm

MULN

Mullen Automotive has regained full compliance with Nasdaq's listing requirements, leading to the cancellation of a previously scheduled panel hearing. The company will continue its listing on the Nasdaq Capital Market.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 1:03 pm

AMLX

Amylyx Pharmaceuticals announced positive topline results from its Phase 2 HELIOS trial for AMX0035 in treating Wolfram Syndrome. The trial showed sustained improvements in pancreatic function and stabilization across secondary endpoints. The company plans to proceed with Phase 3 trials and FDA discussions in 2025.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 1:02 pm

AAPL

AMZN

GOOGL

MSFT

QCOM

The EU's NIS 2 cybersecurity directive is now enforceable, requiring companies to enhance cybersecurity or face fines up to $10M. This impacts major tech firms like Apple, Microsoft, Alphabet, Amazon, and Qualcomm, amid broader EU regulatory efforts.

Portfolio Pulse from Pooja Rajkumari

October 17, 2024 | 1:02 pm

DBEU

SPEU

The European Central Bank (ECB) has lowered interest rates by 25 basis points, marking its first back-to-back cuts in 13 years. This decision is part of efforts to manage inflation, which is expected to rise before stabilizing at the 2% target next year. European markets reacted positively, with the Stoxx 600 index rising. Investors are monitoring ETFs like Xtrackers MSCI Europe Hedged Equity ETF (DBEU) and SPDR Portfolio Europe ETF (SPEU) for market reactions.

Portfolio Pulse from Erica Kollmann

October 17, 2024 | 12:55 pm